Clarity Pharmaceuticals signs copper-67 supply agreement with ISU Idaho Accelerator Center
SYDNEY, AUSTRALIA – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the signing of a Product Supply Agreement with the Idaho State University Idaho Accelerator Center (IAC) for the production and commercial supply of copper-67 (Cu-67).
By By Andrew Taylor, Assistant Marketing Director |
March 12, 2020